Compare Vanguard Information Technology Index Fund ETF (VGT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Information Technology Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Information Technology Index Fund ETF trades at $127.86 (market cap $170.20B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 84.3× GeneDx Holdings Corp's market cap, and Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and GeneDx Holdings Corp for 19 Days on average.
| VGT | WGS | |
|---|---|---|
Market Cap | $170.20B | $2.02B |
Volume | 5,132,883 | 734,640 |
52-Week High | $129.79 | $167.51 |
52-Week Low | $83.59 | $34.51 |
Typical Hold Time | 129 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VGT trades at $127.78, down 1.23% today but maintains a bullish technical outlook with strong moving average signals. The ETF, focused on U.S. technology stocks, has delivered exceptional historical returns, averaging over 17% annually. Recent news highlights its low expense ratio and concentration in tech giants like Nvidia, Apple, and Microsoft. A dividend of $0.15 is scheduled for September 2026.
Long-term growth prospects remain favorable given tech sector dominance and AI momentum, but risks include sector concentration, valuation concerns, and potential AI slowdown. Institutional ownership is increasing, with firms like Baird Financial raising stakes significantly. The current price near pivot point resistance at $128 suggests near-term consolidation before potential breakout.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
